Inflammatory Bowel Diseases最新文献_第4页

Enhancing Inflammatory Bowel Disease (IBD) competency in gastroenterology fellowship through traditional, digital, and experiential learning pathways. 通过传统的、数字化的和体验式的学习途径，增强胃肠病学奖学金中炎症性肠病（IBD）的能力。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag043

Aimen Farooq, Mariam Naveed, Reezwana Chowdhury, Jennifer Seminerio, Joseph Sleiman

{"title":"Enhancing Inflammatory Bowel Disease (IBD) competency in gastroenterology fellowship through traditional, digital, and experiential learning pathways.","authors":"Aimen Farooq, Mariam Naveed, Reezwana Chowdhury, Jennifer Seminerio, Joseph Sleiman","doi":"10.1093/ibd/izag043","DOIUrl":"10.1093/ibd/izag043","url":null,"abstract":"The rapidly evolving field of Inflammatory Bowel Disease (IBD) places growing educational demands on gastroenterology trainees, many of whom report gaps in confidence and preparedness in managing IBD across diverse clinical settings. This article provides a practical, inclusive framework to support gastroenterology fellows in achieving core competency in IBD care while outlining scalable pathways for those interested in developing specialized expertise. Traditional resources such as major conferences, society guidelines, consensus statements, and peer-reviewed journals form the foundation of evidence-based training. Equally vital, however, are opportunities to refine cross-disciplinary skills through close collaboration with radiology, pathology, and endoscopy teams. Visiting observerships at leading IBD centers can be pivotal for immersive, hands-on exposure to complex case management and multidisciplinary care models. The article highlights a growing array of digital and longitudinal learning platforms including webinars, educational websites, podcasts, and programs such as virtual grand rounds, IBD Live, IBD-EII, and IBD REACH that offer flexible, accessible, and globally connected learning experiences. Additionally, it underscores the importance of mentorship, leadership development, and institutional support from program directors in fostering individualized IBD training tracks. By integrating traditional educational foundations with innovative, accessible non-traditional resources and platforms, this guide positions IBD training within a framework of inclusivity, equity, and lifelong learning.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2016-2024"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From visibility to valuation: quantifying between-visit care in pediatric IBD. 从可见性到评估：量化小儿IBD的访间护理。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag124

Jeannie S Huang, Laura E Bauman, David Katibian, David Brent Polk

引用次数: 0

Author's response to the editorial commentary, "TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy". 作者对《IBD中的TL1A和DR3：从粘膜免疫病理到靶向治疗的新时代》社论评论的回应。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag136

Suresh de Silva

引用次数: 0

Chronic opioid use and the risk of infections and death in patients with inflammatory bowel disease: a nationwide cohort study based on real-world data. 慢性阿片类药物使用与炎症性肠病患者感染和死亡风险：一项基于真实世界数据的全国性队列研究

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag085

Bente Mertz Nørgård, Kevin Erichsen Zeiss, Rahul S Dalal, Ken Lund, Mette Louise Andersen, Jens Kjeldsen, Torben Knudsen, Jan Nielsen

{"title":"Chronic opioid use and the risk of infections and death in patients with inflammatory bowel disease: a nationwide cohort study based on real-world data.","authors":"Bente Mertz Nørgård, Kevin Erichsen Zeiss, Rahul S Dalal, Ken Lund, Mette Louise Andersen, Jens Kjeldsen, Torben Knudsen, Jan Nielsen","doi":"10.1093/ibd/izag085","DOIUrl":"10.1093/ibd/izag085","url":null,"abstract":"Background: Chronic opioid use (COU) is frequent in inflammatory bowel disease (IBD), but data on its association with infections and mortality are scarce. We examined (1) hospital-diagnosed infections, (2) prescribed systemic antibiotic/antiviral/antifungal agents, and 3) death associated with COU, and assessed these outcomes according to opioid strength.Methods: This nationwide cohort study included all prevalent adult patients with Crohn disease (CD) and ulcerative colitis (UC) in Denmark from January 1, 2000, to June 30, 2023. Chronic opioid use (COU) was a time-varying exposure (≥3 opioid prescriptions within 12 months, with ≥ 30 days between each prescription). Cox regression models were used to estimate adjusted hazard ratios (aHRs), including baseline and time-varying covariates (IBD surgery, IBD medications, and psychotropic medications).Results: We included 18 897 patients with CD, of whom 3948 (20.9%) had COU. Among those with COU, the aHRs for hospital-diagnosed infections, prescribed antibiotics, and death were 1.91 (95% CI, 1.79-2.04), 1.47 (95% CI, 1.40-1.56), and 1.76 (95% CI, 1.58-1.96), respectively. We included 32 947 patients with UC, of whom 4779 (14.5%) had COU. Among those with COU, the aHRs for hospital-diagnosed infections, prescribed antibiotics, and death were 1.93 (95% CI, 1.80-2.06), 1.56 (95% CI, 1.47-1.65), and 1.74 (95% CI, 1.60-1.90), respectively. Both strong and weak opioids were associated with these adverse outcomes in CD and UC.Conclusions: Real-world data have demonstrated an association between COU and increased risks of infections and mortality, independent of opioid strength, affecting users of both strong and weak opioids. Clinicians should be attentive to these risks when prescribing opioids to this population.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1919-1927"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond calprotectin: where leucine-rich α2-glycoprotein may fit in small bowel Crohn disease monitoring. 钙保护蛋白之外：富含亮氨酸的α2糖蛋白可能适用于小肠克罗恩病监测。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag165

Rajsavi Anand, Andres J Yarur

引用次数: 0

Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis. 晚期治疗开始对慢性眼袋炎患者抗生素依赖的影响。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag086

Yushan Pan, Katie A Dunleavy, Ashwin N Ananthakrishnan

{"title":"Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis.","authors":"Yushan Pan, Katie A Dunleavy, Ashwin N Ananthakrishnan","doi":"10.1093/ibd/izag086","DOIUrl":"10.1093/ibd/izag086","url":null,"abstract":"Background: A quarter of patients with ulcerative colitis who undergo total proctocolectomy with ileal pouch-anal anastomosis experience chronic pouchitis. While advanced therapies (ATs) are effective in some patients, their impact on antibiotic dependence is unclear.Methods: In a multicenter, retrospective study, we identified adults with chronic pouchitis during treatment with AT. Those with complete pre-AT antibiotic data formed the \"incident AT user\" cohort. Those with only post-AT data formed the \"prevalent AT user\" cohort. Antibiotic prescription was modeled as percentage of time, calculated as the number of weeks of antibiotic prescription during the weeks of observed time. The pooled prevalence of antibiotic use during AT was calculated in a systematic review and meta-analysis,.Results: Of the 67 incident AT users, 24 (36%) initiated treatment with tumor necrosis factor-α antagonist, 17 (25%) with anti-integrin, 23 (34%), with interleukin (IL) inhibitors (anti-IL), and 3 (5%) with Janus kinase inhibitors. The mean time on antibiotics was unchanged from 38% to 33% after AT initiation, and 61% of patients (n = 44) had a reduction in antibiotic use. Compared to the patients without reduction, the reduction group had a higher proportion of patients on anti-IL (46% vs 15%, adjusted odds ratio [OR] 11.1; 95% CI, 2.12-57.62). There were no differences in disease-related parameters. Seventy-nine percent (22/28) of prevalent AT users required antibiotics. On meta-analysis, pooled prevalence of antibiotic use was 0.46 (95% CI, 0.35-0.57).Conclusions: Just over half of patients on AT for chronic pouchitis saw reduced antibiotic use; however, further studies are needed to identify impact of AT on antibiotic use and define which patients benefit from immune-mediated vs microbiome-directed therapy.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1910-1918"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the letter to the editor: "pediatric bowel-wall thickness cutoffs: calibration before implementation". 回复给编辑的信：“儿科肠壁厚度临界值：实施前校准”。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag132

Laura Räisänen

引用次数: 0

Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study. 代谢组学预测小儿IBD对VedoKids的治疗反应：来自前瞻性VedoKids队列研究的结果

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag154

Ricardo G Suarez, Ori Bar Or, Esther Orlanski-Meyer, Zivia Shavit, Asaf Azulay, Efrat Broide, Darja Urlep, Art Kastl, Jeffrey S Hyams, Jeremiah Levine, Joel Rosh, Richard K Russell, Dan Turner, Eytan Wine

{"title":"Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.","authors":"Ricardo G Suarez, Ori Bar Or, Esther Orlanski-Meyer, Zivia Shavit, Asaf Azulay, Efrat Broide, Darja Urlep, Art Kastl, Jeffrey S Hyams, Jeremiah Levine, Joel Rosh, Richard K Russell, Dan Turner, Eytan Wine","doi":"10.1093/ibd/izag154","DOIUrl":"10.1093/ibd/izag154","url":null,"abstract":"Background and aim: Metabolites produced through host-microbe interactions may help associate metabolomic signatures with therapy response. We aimed to assess serum metabolites as predictors of vedolizumab remission in children with IBD.Methods: VedoKids was a multicenter, prospective cohort study of children initiating vedolizumab at any stage of disease. Serum metabolomic profiling was performed at baseline (W0), week 14 (W14), and week 30 (W30) using quantitative metabolomics based on DI/LC-MS/MS method. Random Forest (RF) models with maximum relevance-minimum redundancy (mRMR) feature selection, integrated clinical and metabolomic features to predict clinical remission at the next time point (ie, week 0 to week 14; week 14 to week 30; week 30 to week 54).Results: One hundred thirty-eight patients were included (mean age 13.6 years), 64 with Crohn disease (CD) and 74 with ulcerative colitis (UC). In CD, models achieved an area under the receiver operating characteristic curve (AUROC) of 0.80 (95% CI, 0.68-0.92) for predicting response to vedolizumab at W14, 0.92 (95% CI, 0.85-0.99) at W30 , and 0.83 (95% CI, 0.72-0.94) at W54. Metabolites appeared among the most important features, notably PC ae C36:4, citric acid, and malic acid. In UC, corresponding AUROC were 0.72 (95% CI, 0.59-0.85) at W14, 0.77 (95% CI, 0.64-0.90) at W30, and 0.90 (95% CI, 0.80-1.00) at W54. LysoPC a C26:1, picolinic acid, and serotonin were among the most important metabolites for prediction.Conclusions: We identified serum metabolites associated with vedolizumab remission in children with IBD, several of which have been previously linked to IBD pathophysiology.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1880-1887"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis. IBD肠外表现的先进疗法：系统回顾和荟萃分析。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag075

Karan Sachdeva, Dhruv Manik, Tarun Chhibba, Ashwin Ananthakrishnan

{"title":"Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.","authors":"Karan Sachdeva, Dhruv Manik, Tarun Chhibba, Ashwin Ananthakrishnan","doi":"10.1093/ibd/izag075","DOIUrl":"10.1093/ibd/izag075","url":null,"abstract":"Background and aims: Extraintestinal manifestations (EIMs) occur in one-fifth of patients with inflammatory bowel diseases (IBDs) (Crohn's disease[CD]; ulcerative colitis [UC]). As advanced therapies (ATs) for IBD become more targeted, effectiveness for luminal disease may not be extrapolatable to EIMs. We conducted a systematic review to evaluate the efficacy of ATs on EIMs in IBD.Methods: We conducted searches in PubMed/Embase (inception March 2025) for studies of any of the 5 FDA approved AT classes (tumor necrosis factor [TNF] antagonists, Janus kinase [JAK] inhibitors, anti-integrins, anti-interleukins [anti-ILs], and S1P receptor modulators) for musculoskeletal (arthritis, arthralgias), dermatologic (erythema nodosum, pyoderma gangrenosum), or ocular EIMs in patients with IBD. The primary outcome was clinical improvement. The pooled improvement rates by EIM type and AT class were calculated using a random effects model to account for anticipated heterogeneity.Results: A total of 49 studies were included in the final analysis (6 randomized clinical trials [RCTs], 1 pooled analysis of clinical trials, and 42 observational studies). For musculoskeletal EIMs, TNF antagonists achieved response in 61% of patients, with higher response rates for peripheral (73%) than axial (57%) arthritis. JAK inhibitors were similarly effective (65%) while vedolizumab had significantly lower efficacy (42% improvement), particularly for axial arthritis (12%). For dermatologic EIMs, systemically directed ATs had high efficacy (TNF antagonists 89%, anti-IL 91%). There was a paucity of data on ocular EIMs.Conclusion: Systemically directed ATs (TNF-antagonists, JAK inhibitors, anti-ILs) demonstrated strong efficacy for musculoskeletal or cutaneous EIMs; vedolizumab achieved clinical response in lower rates, particularly for axial arthritis.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2050-2060"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy. IBD的TL1A和DR3：从粘膜免疫病理到靶向治疗的新时代。

IF 5.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2026-10-01 DOI: 10.1093/ibd/izag116

Randy S Longman

引用次数: 0